Improving the understanding of side effects in breast cancer treatments
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
This study is looking at how breast cancer treatments affect patients by gathering their feedback on side effects, so doctors can better understand and support those who might struggle with their treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10472654 on NIH RePORTER |
What this research studies
This research focuses on developing advanced methods to assess and report the side effects experienced by patients undergoing breast cancer treatment. By utilizing patient-reported outcomes, the study aims to capture valuable insights into how tolerable various treatments are, including immunotherapies and targeted agents. The goal is to analyze data from clinical trials to identify patterns in adverse events and create a new standard for reporting these experiences over time. This information will help healthcare providers better support patients who may be at risk of discontinuing treatment due to side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are women undergoing treatment for breast cancer, particularly those receiving immunotherapy or targeted therapies.
Not a fit: Patients who are not currently receiving treatment for breast cancer or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of side effects in breast cancer treatments, enhancing patient adherence and overall treatment outcomes.
How similar studies have performed: Previous research has shown success in utilizing patient-reported outcomes to improve treatment tolerability assessments, indicating that this approach is both promising and validated.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Gray, Robert J — Dana-Farber Cancer Inst
- Study coordinator: Gray, Robert J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.